ASGCT Annual Meeting
  • Registration
  • Abstracts
    • Submission and Presentation Information
    • Award Recipients
    • Abstract Topic Categories
    • Awards and Incentives
  • Program
    • Pre-Meeting Workshops: May 10, 2021
    • May 11, 2021
    • May 12, 2021
    • May 13, 2021
    • May 14, 2021
    • Plenary Speakers
  • Sponsor and Exhibit
    • Current Sponsors
    • Pre-Show Exhibitor Listing
  • Contact Us
  • www.asgct.org
Quick Links
  • ASGCT.org

Connect with us

ASGCT Annual Meeting

  • Registration
  • Abstracts
    • Submission and Presentation Information
    • Award Recipients
    • Abstract Topic Categories
    • Awards and Incentives
  • Program
    • Pre-Meeting Workshops: May 10, 2021
    • May 11, 2021
    • May 12, 2021
    • May 13, 2021
    • May 14, 2021
    • Plenary Speakers
  • Sponsor and Exhibit
    • Current Sponsors
    • Pre-Show Exhibitor Listing
  • Contact Us
  • www.asgct.org
×

Abstract Topic Categories

When submitting an abstract, authors will select one first choice topic and one second choice topic from the list below that best describes their abstract:

A1 – RNA Virus Vectors
A2 – AAV Vectors – Virology and Vectorology
A3 – AAV Vectors – Preclinical and Proof-of-Concept Studies
A4 – AAV Vectors – Clinical Studies

B – Gene Targeting and Gene Correction (Basic development of novel technologies for genome editing, with or without site-specific endonuclease. Gene targeting projects focused on specific disease applications are strongly encouraged to submit abstracts to the suitable tissue/disease related category.)
C – Oligonucleotide Therapeutics (siRNAs, aptamers, antagomirs, miRNAs, shRNA, antisense, and splice switching oligos, plasmids)
D – Synthetic/Molecular Conjugates and Physical Methods for Delivery of Gene Therapeutics (Including exosomes)
E1 – Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases
E2 – Cardiovascular and Pulmonary Diseases

E3 – Neurologic Diseases (Including Ophthalmic and Auditory Diseases)
E4 – Musculo-skeletal Diseases
E5 – Cancer – Immunotherapy, Cancer Vaccines
E6 – Cancer – Oncolytic Viruses
E7 – Cancer – Targeted Gene and Cell Therapy
E8 – Hematologic and Immunologic Diseases

F – Immunological Aspects of Gene Therapy and Vaccines (Includes host responses, therapy/prevention of infectious diseases; excludes cancer immunotherapy and cancer vaccines)
G – Cell Therapies (Includes development of somatic, embryonic and induced pluripotent stem cells or other therapeutic cell populations, and issues related to cell expansion or processing)
H1 – Vector Product Engineering, Development or Manufacturing
H2 – Cell Therapy Product Engineering, Development and Manufacturing
H3 – Pharmacology/Toxicology Studies or Assay Development

Important Dates

Call for Abstracts Opens
November 16, 2020

Registration Opens
December 8, 2020

Call for Abstracts Closes
January 27, 2021

Abstract Notifications Sent
April 5, 2021

Abstract Withdrawal Date
April 12, 2021

Abstracts Released to the Public
April 27, 2021

Early Registration Closes
May 1, 2021

24th ASGCT Annual Meeting
May 11 – 14, 2021

 

ASGCT_Web_Horz_Red-White.png

Office

American Society of Gene & Cell Therapy
20800 Swenson Dr.
Suite 300
Waukesha, WI 53186 USA
Tel: 414.278.1341
Fax: 414.276.3349
Email: info@asgct.org

Quick Links

  • ASGCT 2020 Homepage
  • Registration
  • Abstracts
  • Hotel & Travel
  • Program
  • Exhibitors & Sponsors
  • Media
  • Contact ASGCT

Follow Us

© 2021 American Society of Gene & Cell Therapy. All rights reserved.